1 mL BAC
1 units
resulting U-100 draw
- Concentration
- 20 mg/mL
- BAC added
- 1 mL
SinglePreclinicalPreclinicalVery Low confidenceSourced
Ovagen
A peptide bioregulator marketed for ovarian and endocrine claims. Robust indexed human evidence is insufficient to establish a reproducible protocol.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Vial arithmetic for the subcutaneous Ovagen quantities recorded in an online research community archive. These conflicting bioregulator conventions are not validated human schedules.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported cycle phases
Select a point for its calculation examples- Daily for 10-20 days200 mcgThis is the upper end of the same archived 100-200 mcg daily convention, not a controlled dose-finding result.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 200 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw3 U
20-30 U reference band
2 mL BAC
2 units
resulting U-100 draw
- Concentration
- 10 mg/mL
- BAC added
- 2 mL
3 mL BAC
3 units
resulting U-100 draw
- Concentration
- 6.667 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Community GuideSubcutaneous in guideDaily
Third-party educational bioregulator schedule
10 mcg daily in weeks 1-2, 20 mcg in weeks 3-4, 50 mcg in weeks 5-6 and 100-150 mcg in weeks 7-16
No matched controlled human study validates these very small quantities or the proposed route. The schedule is retained only as low-confidence provenance.
View sourceCommunity GuideOral, subcutaneous or intramuscular in reportsDaily during 10-20 day courses
online research community bioregulator spotlight
The spotlight states 20-40 mg orally before meals for 10-20 days or 0.1-0.2 mg subcutaneously or intramuscularly daily for 10-20 days
A later AI-supported community post instead proposes 2 mg subcutaneously daily for 10 days and openly questions the spotlight. Its purported study citations were not independently verified; raw/bioregulators/bio-ovagen.md:23-25 and 35-113.
View sourceEvidence Gap
authenticated research-forum (Peppys) Ovagen category
No usable community dose is reported; the captured archive holds only two category-description stubs, an unanswered request for any research experience, and a vendor announcement of a 20 mg vial, with no dosing, route, frequency or protocol content
Despite an Ovagen bioregulator topic existing on the forum, no community-derived schedule or quantities were posted, and usernames are omitted. This is an evidence gap recorded as provenance, not a validated or even a community-suggested regimen.
View sourceEvidence summary
A peptide bioregulator marketed for ovarian and endocrine claims. Robust indexed human evidence is insufficient to establish a reproducible protocol.
Protocol basis
The page records the sparse evidence base and therefore provides no invented administration schedule.
Community provenance (Peppys)
An authenticated research-forum archive was checked for Ovagen and found to contain no usable dosing material. The captured threads are limited to two category-description stubs, an unanswered request for any research experience, and a vendor product announcement, with no dose, route, frequency or protocol recorded. This is logged as an evidence gap rather than a schedule; usernames are omitted and no community quantity exists to reproduce.
What remains uncertain
Identity, human exposure, fertility effects, interactions, safety and controlled efficacy are unknown.
Warnings and contraindications
No adequate controlled human regimen was identified in major indexed literature.
Reproductive and endocrine claims require specialist clinical evidence.
Vendor schedules cannot substitute for matched formulation and outcome data.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.